Trial Profile
An Open-label, Multicenter Phase 1 Study to Characterize the Safety, Tolerability, Preliminary Antileukemic Activity, Pharmacokinetics, and Maximum Tolerated Dose or Pharmacological Active Dose of BAY2402234 in Patients With Advanced Myeloid Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 Jan 2022
Price :
$35
*
At a glance
- Drugs Orludodstat (Primary)
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 03 Mar 2021 Status changed from recruiting to discontinued.
- 31 Jul 2020 Planned End Date changed from 10 Jan 2023 to 10 Apr 2023.
- 31 Jul 2020 Planned primary completion date changed from 10 Jan 2022 to 10 Apr 2022.